Immuneering's Atebimetinib Shows Promising Survival Data in Pancreatic Cancer Trial — Immuneering Corporation

Event summary

Immuneering reported a 17.3-month median overall survival in first-line pancreatic cancer patients treated with atebimetinib and chemotherapy, presented at the ASCO Annual Meeting on June 1, 2026.
The Phase 3 MAPKeeper 301 trial is underway, with over 30 study locations posted to date.
Peer-reviewed publication in Cancer Research detailed atebimetinib’s broad preclinical activity and favorable tolerability across RAS- and RAF-mutant tumors.
Immuneering ended Q2 2026 with $182.7 million in cash, anticipating runway into 2029.

The big picture

Immuneering’s promising data for atebimetinib in pancreatic cancer positions it as a potential best-in-class treatment, addressing a critical unmet need. The company’s focus on Deep Cyclic Inhibitors differentiates its approach in the competitive oncology space, but success hinges on executing Phase 3 trials and securing regulatory approvals. With a strong cash position, Immuneering has the financial flexibility to advance multiple programs, though sustaining this momentum will be key.

What we're watching

Clinical Trial Progress: The pace at which the Phase 3 MAPKeeper 301 trial enrolls and reports data will determine atebimetinib’s potential regulatory approval timeline.
Combination Therapy Potential: Whether atebimetinib can sustain its favorable tolerability profile in combination with anti-PD-1 therapies, particularly in non-small cell lung cancer.
Financial Sustainability: How Immuneering manages its cash burn rate to extend its runway beyond 2029, given the increasing R&D expenses.